Rivaroxaban Benefits LER Patients Safely Regardless of Chronic Kidney Disease - MD Magazine

VOYAGER PAD subgroup analyses showed the anticoagulant reduced likelihood of hospitalization without increasing bleeding risk in patients with CKD.

A subgroup analysis from the VOYAGER PAD trial showed anticoagulant rivaroxaban (Xarelto) was associated with reduced coronary or peripheral events resulting hospitalization among patients with recen… [+2022 chars]

full article...